- Avicanna (AVCN) has completed a commercial export of purified cannabigerol (CBG) into the Czech Republic
- This marks the company’s first commercial export of CBG into the European Union
- Aureus branded CBG is cultivated through organic certified and sustainable practices at Avicanna’s Santa Marta Golden Hemp (SMGH) facilities
- CBG has strong anti-inflammatory properties, making it an exciting potential option for formulating topical treatments for arthritis, and muscle and joint pain
- Avicanna is a commercial-stage biopharmaceutical company focused on developing cannabinoid-based products
- Avicanna Inc. (AVCN) opened trading at C$0.86 per share
Avicanna (AVCN), through its Colombian subsidiary, has completed a commercial export of purified cannabigerol (CBG) into the Czech Republic.
The completed export into the Czech Republic marks the company’s first commercial export of CBG into the European Union.
Aureus branded CBG is cultivated through organic certified and sustainable practices at Avicanna’s Santa Marta Golden Hemp (SMGH) facilities. The CBG is also extracted and purified through Avicanna’s proprietary processes to provide an isolated and purified form.
CBG has strong anti-inflammatory properties, making it an exciting potential option for formulating topical treatments for arthritis, and muscle and joint pain, as well as prospective oral treatments to address gut inflammation on a cellular level.
Avicanna is a commercial-stage biopharmaceutical company focused on cannabinoid research, development and evidence-based products.
Avicanna Inc. (AVCN) opened trading at C$0.86 per share.